Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Receivables (2016 - 2025)

Veracyte's Change in Receivables history spans 14 years, with the latest figure at -$3.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 58.21% year-over-year to -$3.2 million; the TTM value through Dec 2025 reached $708000.0, down 88.95%, while the annual FY2025 figure was $708000.0, 88.95% down from the prior year.
  • Change in Receivables for Q4 2025 was -$3.2 million at Veracyte, down from -$425000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $7.1 million in Q1 2025 and bottomed at -$3.2 million in Q4 2025.
  • The 5-year median for Change in Receivables is $451000.0 (2022), against an average of $814600.0.
  • The largest annual shift saw Change in Receivables skyrocketed 1674.79% in 2021 before it tumbled 383.72% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $2.3 million in 2021, then crashed by 93.92% to $139000.0 in 2022, then skyrocketed by 448.92% to $763000.0 in 2023, then tumbled by 360.94% to -$2.0 million in 2024, then tumbled by 58.21% to -$3.2 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Change in Receivables are -$3.2 million (Q4 2025), -$425000.0 (Q3 2025), and -$2.8 million (Q2 2025).